Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
ARCHIVE: eXoZymes launches subsidiary, NCTx, to unlock a promising compound for gut and liver health
press releaseinvestornutraceuticalsmedicinescienceARCHIVE
ARCHIVE: eXoZymes launches subsidiary, NCTx, to unlock a promising compound for gut and liver healthMay 6, 2025
ARCHIVE: AI transforming biotechnology: From form with AlphaFold to function with exozymes
investorvideoscienceARCHIVE
ARCHIVE: AI transforming biotechnology: From form with AlphaFold to function with exozymesApril 28, 2025
Dr. Tyler Korman, co-founder and VP of Research at eXoZymes, is excited about the 'exozymes' cover story in GEN Biotechnology, which is freely available as an Open Access paper.
press releaseinvestorvideoscienceARCHIVEkorman
ARCHIVE: GEN Biotechnology cover story: Bringing clarity and precision to the cell-free space by introducing exozymesApril 21, 2025
GEN Biotechnology
sciencepublicationARCHIVE
ARCHIVE: GEN Biotechnology: Exozymes for Biomanufacturing: Toward Clarity and Precision in the Cell-Free Space (cover story)April 17, 2025
ARCHIVE: Bloomberg TV: Jane King interviews co-founder and VP of Research, Dr. Tyler Korman
investorpress clippingsvideoscienceARCHIVEkorman
ARCHIVE: Bloomberg TV: Jane King interviews co-founder and VP of Research, Dr. Tyler KormanApril 15, 2025
BioClick - an enzyme engineering game-changer
press releaseinvestorscienceARCHIVEkorman
ARCHIVE: BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grantApril 10, 2025
ARCHIVE: World Bio Market Insights: eXoZymes appoints Damien Perriman as Chief Commercial Officer
investorpress clippingsARCHIVEperriman
ARCHIVE: World Bio Market Insights: eXoZymes appoints Damien Perriman as Chief Commercial OfficerApril 3, 2025
ARCHIVE: Transcript: eXoZymes 4th quarter and full Year 2024 update from April 2, 2025
investorARCHIVE
ARCHIVE: Transcript: eXoZymes 4th quarter and full Year 2024 update from April 2, 2025April 3, 2025
ARCHIVE: eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
talentpress releaseinvestorvideoARCHIVEperriman
ARCHIVE: eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCOApril 2, 2025
ARCHIVE: eXoZymes Provides Fourth Quarter and Full Year 2024 Update
press releaseinvestorARCHIVE
ARCHIVE: eXoZymes Provides Fourth Quarter and Full Year 2024 UpdateApril 2, 2025
Previous page
Page 11 of 16
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark